Mogrify, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has launched EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.
EpiMOGRIFY is an extension of the Company’s proprietary direct cellular conversion technology, MOGRIFY, and enables the identification of the optimal culture conditions required to maintain cells in chemically defined media. This can be applied in cGMP manufacture and enhances directed differentiation or cell conversion to support the development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.
EpiMOGRIFY combines gene-regulatory information with a model of a cell’s epigenetic landscape and leverages changes in the level of DNA-histone methylation (H3K4me3 modifications). The platform utilizes data from more than 100 human cell/tissue types (available via the ENCODE and Epigenome Roadmap consortia) to accurately define culture conditions that can maintain the cell identity or induce cell conversion.
The predictive power of EpiMOGRIFY has been validated in two ways: cell maintenance and differentiation. EpiMOGRIFY-predicted factors are able to maintain astrocytes and cardiomyocytes in vitro in chemically defined media and promote the generation of astrocytes and cardiomyocytes from neural progenitors and embryonic stem cells, respectively. In both cell maintenance and differentiation, EpiMOGRIFY defined conditions performed as well as or better in all cases when compared to existing undefined conditions, significantly increasing cell growth and survival, as well as resulting in a higher differentiation efficiency.
For more information, visit: https://mogrify.co.uk/science/#epimogrify Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/8_PRODUCT_MOGRIFY.jpg29910003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:03:002021-01-14 11:39:19Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance
TESTA Analytical Solutions has developed a new flowmeter which enables continuous measurement of flow rate without interference in chromatography systems.
Flow rate is one of the most important parameters in any liquid chromatography system, it determines retention time or volume and has by nature a major influence on reproducibility.
Compatible with all HPLC and GPC/SEC solvents, the new TESTA flowmeter is conveniently sized and powers itself from a USB connection. A PC-based app allows continuous recording and storage of the measured flow rates. The current flow rate is also displayed on the flowmeter’s integral high-resolution OLED display, allowing easy control of current flow value.
Extraordinary high resolution and wide dynamic range makes the TESTA flowmeter the perfect flow monitoring tool for the most demanding HPLC and GPC/SEC systems.
The new high-resolution flowmeter is available as an off-the-shelf unit and also can be tailored as an optimized OEM module for chromatography instrument company’s interesting in taking advantage of this new technology.
For more information, visit: https://testa-analytical.com/flowmeter-request.html Read more
TRIMERO Diagnostics has introduced an IVD CE-marked assay for testing Serum Amyloid A (SAA) on Beckman Coulter’s IMMAGE immunochemical systems.
The key features of the assay are:
specifically developed for IMMAGE and IMMAGE 800 nephelometers
values traced to the Serum Amyloid A (SAA) 1st International Standard (NIBSC code: 92/680) of the WHO.
SAA turbidimetric assays are also available for the most popular clinical chemistry analysers.
Other available assays for IMMAGE nephelometers and turbidimetry include: KLoneus Free Light Chains (FLC) for serum and urine, Beta-2 Microglobulin for serum and urine, IgD Immunoglobulins, Retinol Binding Protein (RBP) for serum and urine, Soluble Transferrin Receptor (sTfR), Hemopexin, Cystatin-C for serum and urine, A1-Microglobulin, Kappa and Lambda Light Chains for serum and urine, Complement C1q, Complement C5, Factor B (C3 Proactivator), C1 (Esterase) Inhibitor.
For more information, visit: www.3diag.com Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:01:002021-01-14 11:32:35TRIMERO Diagnostics introduces Serum Amyloid A nephelometric assay
H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimization, safety and scale-up, has released its new laboratory automation software labCONSOL, designed to support customers in the automation and coordination of laboratory equipment. The software, which builds on the company’s proven ‘WinISO’ technology, introduces a new and intuitive user interface, and provides a scalable platform for future development.
Incorporating the next generation of H.E.L’s WinISO software engine, labCONSOL introduces new features that enable scientists to improve lab efficiency and boost productivity. Delivered within an improved user experience, the platform combines rapid data capture modes, an advanced real-time data display engine, and automated monitoring of experiment completion and failure states. In practical terms, these features enable researchers to easily and accurately track how an experiment is proceeding, focusing on the most critical aspects, ultimately avoiding unnecessary repeated lab work, which can be both costly and time-consuming.
For existing H.E.L product users, labCONSOL guarantees a quick and seamless transition with minimal retraining.
H.E.L systems will shortly start shipping with labCONSOL installed, and for the majority of existing users, the new software will be available as part of ongoing service plans. All customers with active service cover plans will receive regular, automatic labCONSOL updates that will continuously upgrade the software’s capabilities and enrich the user experience.
For more information, visit www.helgroup.com Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/11_PRODUCT_HELGROUP.jpg54310003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:00:002021-01-14 11:32:05H.E.L Group launches labCONSOL laboratory automation software
by Dr Elena Sukhacheva Early diagnosis and fast treatment of sepsis is crucial for obtaining the best outcome possible for the patient. However, diagnosis is not easy clinically and the complexity of the condition means that there is not an obvious individual biomarker for it. However, research in recent years has shown that monocyte distribution width is an easily measured parameter that is able to discriminate sepsis from non-sepsis, particularly when combined with the patient’s white blood count.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:05:002021-01-18 14:47:44Monocyte distribution width: new biomarker for sepsis diagnosis
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/10_NOVA_BIOMEDICAL.jpg143810003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Largest Selection of Critical Care Test Menus and Models
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/9_AD_BIO-RAD.jpg136910003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Detection of IgM, IgA & IgG In One Test
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance
, /in Product News /by 3wmediaMogrify, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has launched EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.
EpiMOGRIFY is an extension of the Company’s proprietary direct cellular conversion technology, MOGRIFY, and enables the identification of the optimal culture conditions required to maintain cells in chemically defined media. This can be applied in cGMP manufacture and enhances directed differentiation or cell conversion to support the development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.
EpiMOGRIFY combines gene-regulatory information with a model of a cell’s epigenetic landscape and leverages changes in the level of DNA-histone methylation (H3K4me3 modifications). The platform utilizes data from more than 100 human cell/tissue types (available via the ENCODE and Epigenome Roadmap consortia) to accurately define culture conditions that can maintain the cell identity or induce cell conversion.
The predictive power of EpiMOGRIFY has been validated in two ways: cell maintenance and differentiation. EpiMOGRIFY-predicted factors are able to maintain astrocytes and cardiomyocytes in vitro in chemically defined media and promote the generation of astrocytes and cardiomyocytes from neural progenitors and embryonic stem cells, respectively. In both cell maintenance and differentiation, EpiMOGRIFY defined conditions performed as well as or better in all cases when compared to existing undefined conditions, significantly increasing cell growth and survival, as well as resulting in a higher differentiation efficiency.
For more information, visit: https://mogrify.co.uk/science/#epimogrify
Read more
TESTA Analytical develops compact, high-res chromatography flowmeter
, /in Product News /by 3wmediaTESTA Analytical Solutions has developed a new flowmeter which enables continuous measurement of flow rate without interference in chromatography systems.
Flow rate is one of the most important parameters in any liquid chromatography system, it determines retention time or volume and has by nature a major influence on reproducibility.
Compatible with all HPLC and GPC/SEC solvents, the new TESTA flowmeter is conveniently sized and powers itself from a USB connection. A PC-based app allows continuous recording and storage of the measured flow rates. The current flow rate is also displayed on the flowmeter’s integral high-resolution OLED display, allowing easy control of current flow value.
Extraordinary high resolution and wide dynamic range makes the TESTA flowmeter the perfect flow monitoring tool for the most demanding HPLC and GPC/SEC systems.
The new high-resolution flowmeter is available as an off-the-shelf unit and also can be tailored as an optimized OEM module for chromatography instrument company’s interesting in taking advantage of this new technology.
For more information, visit: https://testa-analytical.com/flowmeter-request.html
Read more
TRIMERO Diagnostics introduces Serum Amyloid A nephelometric assay
, /in Product News /by 3wmediaTRIMERO Diagnostics has introduced an IVD CE-marked assay for testing Serum Amyloid A (SAA) on Beckman Coulter’s IMMAGE immunochemical systems.
The key features of the assay are:
SAA turbidimetric assays are also available for the most popular clinical chemistry analysers.
Other available assays for IMMAGE nephelometers and turbidimetry include: KLoneus Free Light Chains (FLC) for serum and urine, Beta-2 Microglobulin for serum and urine, IgD Immunoglobulins, Retinol Binding Protein (RBP) for serum and urine, Soluble Transferrin Receptor (sTfR), Hemopexin, Cystatin-C for serum and urine, A1-Microglobulin, Kappa and Lambda Light Chains for serum and urine, Complement C1q, Complement C5, Factor B (C3 Proactivator), C1 (Esterase) Inhibitor.
For more information, visit: www.3diag.com
Read more
H.E.L Group launches labCONSOL laboratory automation software
, /in Product News /by 3wmediaH.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimization, safety and scale-up, has released its new laboratory automation software labCONSOL, designed to support customers in the automation and coordination of laboratory equipment. The software, which builds on the company’s proven ‘WinISO’ technology, introduces a new and intuitive user interface, and provides a scalable platform for future development.
Incorporating the next generation of H.E.L’s WinISO software engine, labCONSOL introduces new features that enable scientists to improve lab efficiency and boost productivity. Delivered within an improved user experience, the platform combines rapid data capture modes, an advanced real-time data display engine, and automated monitoring of experiment completion and failure states. In practical terms, these features enable researchers to easily and accurately track how an experiment is proceeding, focusing on the most critical aspects, ultimately avoiding unnecessary repeated lab work, which can be both costly and time-consuming.
For existing H.E.L product users, labCONSOL guarantees a quick and seamless transition with minimal retraining.
H.E.L systems will shortly start shipping with labCONSOL installed, and for the majority of existing users, the new software will be available as part of ongoing service plans. All customers with active service cover plans will receive regular, automatic labCONSOL updates that will continuously upgrade the software’s capabilities and enrich the user experience.
For more information, visit www.helgroup.com
Read more
Monocyte distribution width: new biomarker for sepsis diagnosis
, /in E-News /by 3wmediaby Dr Elena Sukhacheva
Early diagnosis and fast treatment of sepsis is crucial for obtaining the best outcome possible for the patient. However, diagnosis is not easy clinically and the complexity of the condition means that there is not an obvious individual biomarker for it. However, research in recent years has shown that monocyte distribution width is an easily measured parameter that is able to discriminate sepsis from non-sepsis, particularly when combined with the patient’s white blood count.
Read more
Largest Selection of Critical Care Test Menus and Models
, /in Featured Articles /by 3wmediaDetection of IgM, IgA & IgG In One Test
, /in Featured Articles /by 3wmediaPlatelia SARS-CoV-2 Total Ab Assay
FEATHER Disposable Microtome Blade
, /in Featured Articles /by 3wmediaA custom of sharp craftsmanship
Procalcitonin FS
, /in Featured Articles /by 3wmediaPrecise • Cost-efficient • Time-saving
SARS CoV-2 (COVID-19) External Quality Assurance
, /in Featured Articles /by 3wmediaRaising standards Promoting excellence